Cenderitide
Also known as: CD-NP, CD‑NP, Cenderitide
Source Cenderitide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Cenderitide (CD‑NP) is a synthetic chimeric peptide combining C‑type natriuretic peptide with the C‑terminal tail of dendroaspis natriuretic peptide; it is being studied for heart‑failure and renal‑protective therapy.
Mechanism of Action
Dual activation of natriuretic peptide receptors A (NPR‑A) and B (NPR‑B), increasing intracellular cGMP and producing vasodilation, natriuresis, diuresis, inhibition of the renin‑angiotensin‑aldosterone system and antifibrotic effects
Routes of Administration
Goals & Uses
- Blood pressure reductionCardiovascularLow
- Chronic heart failure treatmentCardiovascularModerate
- Natriuresis and diuresis promotionRenal/CardiovascularModerate
- Renal protection in heart failureRenalLow
- Acute decompensated heart failure managementCardiovascularModerate
- Renal protectionRenalModerate
- Renin-angiotensin-aldosterone system suppressionNeurohormonalModerate
Contraindications
- Cardiogenic shockCardiovascularHigh
- Hypersensitivity to natriuretic peptidesImmunologicalHigh
- Acute decompensated heart failure with high filling pressuresCardiacModerate
- Severe renal failure (anuria)RenalModerate
- Severe hypotensionCardiovascularHigh
Adverse Effects
- Increased serum creatinineRenalUncommon
- Injection site reactionsLocalUncommon
- HeadacheNeurologicCommonPain in the head or upper neck
- HypotensionCardiovascularCommonLow blood pressure
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady
Drug Interactions
- Antihypertensive agentsModerate
- ACE inhibitors / ARBsModerate
- Other vasodilators (e.g., nitrates, ACE inhibitors)Moderate
- DiureticsModerateMay worsen dehydration or electrolyte imbalance
Population Constraints
- Pediatric patientsAgeRelative
- Elderly patients (≥75 years)AgeRelative
- Pregnant womenReproductiveRelative
- Severe hepatic impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionInvestigationalNot approved; clinical studies in progress
- United StatesInvestigationalPhase II trials ongoing
- United KingdomInvestigationalUnder MHRA review for trial authorization
Not approved in any major jurisdiction; currently in Phase II clinical development for chronic heart failure with reduced ejection fraction.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Cenderitide?
Cenderitide (CD‑NP) is a synthetic chimeric peptide combining C‑type natriuretic peptide with the C‑terminal tail of dendroaspis natriuretic peptide; it is being studied for heart‑failure and renal‑protective therapy.
What is Cenderitide used for?
Cenderitide is educationally associated with: Blood pressure reduction, Chronic heart failure treatment, Natriuresis and diuresis promotion, Renal protection in heart failure, Acute decompensated heart failure management, Renal protection, Renin-angiotensin-aldosterone system suppression. Educational only — not medical advice.
How is Cenderitide administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Cenderitide?
Reported adverse effects include: Increased serum creatinine, Injection site reactions, Headache, Hypotension, Nausea, Dizziness. This list is not exhaustive — consult a qualified clinician.
Who should avoid Cenderitide?
Recorded contraindications: Cardiogenic shock, Hypersensitivity to natriuretic peptides, Acute decompensated heart failure with high filling pressures, Severe renal failure (anuria), Severe hypotension. Consult a qualified clinician before use.